Safety and Pharmacokinetics of ODM-209

NCT03878823 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer Metastatic
Advanced Breast Cancer
Castration-resistant Prostate Cancer
Metastatic Breast Cancer

Interventions

DRUG: ODM-209

Sponsor

Orion Corporation, Orion Pharma